VERO Biotech
Transforming The Delivery of Inhaled Nitric Oxide
Transforming The Delivery of Inhaled Nitric Oxide
VERO Biotech is an emerging biotechnology company founded in 2006, with a focus on designing, developing, and commercializing next-generation inhaled nitric oxide (NO) delivery systems. The company's slogan "Transforming The Delivery of Inhaled Nitric Oxide" encapsulates its mission to address unmet medical needs of patients with cardiopulmonary conditions. Based in the United States, Vero Biotech is committed to enhancing the lives of patients by leading the development of innovative technologies for inhaled NO delivery in the acute care hospital setting and beyond, wherever Nitric Oxide treatment is necessary.
With its recent $30.00M Venture Round investment on 11 January 2023 from Petrichor Healthcare, Vero Biotech has attracted the attention of investors in the Biotechnology, Health Care, and Pharmaceutical industries. The company's dedication to exceeding customer expectations in terms of safety, efficacy, and growth, by focusing on the science, development, and commercialization of their innovations, signals a promising future for those considering investment opportunities in the biotechnology sector.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $30.00M | 1 | Petrichor Healthcare Capital Management | 11 Jan 2023 |
| Series E | $100.00M | 1 | MVM Life Science Partners | 21 Dec 2021 |
| Debt Financing | $50.00M | 1 |
|
20 Jan 2021 |
| Venture Round | $29.94M | - | 29 Sep 2017 | |
| Private Equity Round | $14.57M | - | 03 Oct 2013 |
No recent news or press coverage available for VERO Biotech.
We care about your data, and we'd love to use cookies make your experience better.
